Vanda Pharmaceuticals VNDA Q1 2026 Disappoints EPS 082 Below 070 Views Oil Prices Recover Slightly After Sharp Decline on USIran Agreement Optimism K2 Capital KTWOR Declines 500 Amid Market Weakness 20260520 Citigroup C Shows Potential as a LongTerm Value Play in Current Market BioLineRx Ltd BLRX Q3 2024 Earnings Loss Per Share of 007 on No Revenue Shares Surge 9 SuRo Capital Corp 600 Notes due 2026 SSSSL Q1 2026 Earnings Massive EPS Surprise Driven by Investment Gains BancFirst Corporation Q1 2026 Earnings EPS Surpasses Estimates Amid Steady Performance UTSI Q4 2019 Earnings EPS Misses Estimates by Wide Margin JVA Q4 2019 Earnings Significant EPS Miss Stock Rises Modestly BiomX Inc Q4 2025 Earnings Large Earnings Miss Stirs Uncertainty No Revenue Reported